Skip Navigation LinksHome > December 2009 - Volume 52 - Issue 4 > Changes in Cognition During Antiretroviral Therapy: Comparis...
Text sizing:
A
A
A
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0b013e3181c656e2
Erratum

Changes in Cognition During Antiretroviral Therapy: Comparison of 2 Different Ranking Systems to Measure Antiretroviral Drug Efficacy on HIV-Associated Neurocognitive Disorders: Erratum.

Free Access

In the article by Tozzi et al, appearing in the Journal of Acquired Immune Deficiency Syndromes, Vol. 52, No. 1, pp. 56-63, entitled “Changes in Cognition During Antiretroviral Therapy: Comparison of 2 Different Ranking Systems to Measure Antiretroviral Drug Efficacy on HIV-Associated Neurocognitive Disorders,” the central nervous system penetration−effectiveness (CPE) score of atazanavir−ritonavir was misstated twice as 1.0 (high) when it is 0.5 (intermediate).

The Methods section of the abstract, p. 56, should conclude: “… CNS penetration-effectiveness (CPE) score: a summary score of 1 (high penetration: zidovudine, abacavir, delavirdine, nevirapine, amprenavir-ritonavir, fosamprenavir-ritonavir, indinavir-ritonavir and lopinavir-ritonavir), 0.5 (intermediate penetration: stavudine, lamivudine, emtricitabine, efavirenz, amprenavir, fosamprenavir, atazanavir-ritonavir, atazanavir, and indinavir), and 0 (low penetration: remaining ARVs) for each drug in the combination.”

The first full paragraph on p. 58 should read: “The CPE CHARTER score was defined17,18 as a summary score of 1 (high penetration: zidovudine, abacavir, delavirdine, nevirapine, amprenavir-ritonavir, fosamprenavir-ritonavir, indinavir-ritonavir, and lopinavir-ritonavir), 0.5 (intermediate penetration: stavudine, lamivudine, emtricitabine, efavirenz, amprenavir, fosamprenavir, atazanavir-ritonavir, atazanavir, and indinavir), and 0 (low penetration: tenofovir, didanosine, zalcitabine, nelfinavir, saquinavir, saquinavir-ritonavir, ritonavir, tipranavir-ritonavir, and enfuvirtide) for each individual ARV drug in the combination.”

Finally, reference 18 on p. 63 should appear as the following:

18. Clifford DB. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med. 2008;16:94-98.

Due to the very limited atazanavir exposure (3 patients, for a few months) of the study cohort, the regression results were not affected by the ranching position of atazanavir-ritonavir.

This error has been noted in the online version of the article available at www.jaids.com.

Back to Top | Article Outline

REFERENCE

1. Tozzi V, Balestra P, Salvatori MF, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr. 2009;52:56-63.

© 2009 Lippincott Williams & Wilkins, Inc.

Login